Maternal Serum Adropin in Placenta Accreta Spectrum (Adropin)

February 19, 2026 updated by: Gulsum Uysal, Adana City Training and Research Hospital

Maternal Serum Adropin as a Potential Biomarker for Placenta Accreta Spectrum

Aim: To compare maternal serum adropin levels in pregnancies complicated by placenta previa and/or placenta accreta spectrum (PAS) with those of healthy pregnant women and to evaluate the diagnostic value of adropin for predicting placental invasion.

Methods:

This cross-sectional study included 84 singleton pregnancies at ≥34 weeks of gestation: 42 women diagnosed with placenta previa and/or PAS and 42 healthy pregnant women who underwent cesarean delivery. Maternal serum adropin levels are measured preoperatively using enzyme-linked immunosorbent assay. Demographic, obstetric, ultrasonographic, and intraoperative findings were recorded. Receiver operating characteristic (ROC) curve analysis is performed to assess the predictive performance of adropin for PAS.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

84

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
    • Yuregir
      • Adana, Yuregir, Turkey (Türkiye), 01100
        • University of Heath and Science Adana City Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

Pregnant women aged 18-45 years in the reproductive period with singleton, viable third-trimester pregnancies diagnosed with placenta previa and/or PAS were included in the study. The control group consisted of healthy pregnant women in the third trimester with similar demographic characteristics who underwent elective cesarean delivery and had no obstetric or medical comorbidities.

Description

Inclusion Criteria:

  • Pregnant women aged 18-45 years in the reproductive period
  • Singleton, viable third-trimester pregnancies diagnosed with placenta previa and/or PAS

Exclusion Criteria:

  • Uterine anomalies,
  • Chronic systemic diseases,
  • Multiple pregnancies,
  • Obstetric complications such as preterm premature rupture of membranes, threatened preterm labor, fetuses followed for intrauterine growth restriction, and placental abruption.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Study group (Diagnosed with Plasenta Previa and/or Placenta accreta spectrum)
Pregnant women aged 18-45 years viable third-trimester pregnancies diagnosed with placenta previa and/or PAS (Placenta accreta spectrum)
control group
healthy pregnant women in the third trimester with similar demographic characteristics

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood serum Adropin levels
Time Frame: From 15.04.2024 to 01.04.2025
The aim of the present study was to evaluate maternal serum adropin levels in pregnancies complicated by placenta previa and placenta accreta spectrum and compare to healthy controls.
From 15.04.2024 to 01.04.2025

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Adana City Training and Research Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 15, 2024

Primary Completion (Actual)

April 1, 2025

Study Completion (Actual)

April 1, 2025

Study Registration Dates

First Submitted

February 12, 2026

First Submitted That Met QC Criteria

February 12, 2026

First Posted (Actual)

February 19, 2026

Study Record Updates

Last Update Posted (Actual)

February 20, 2026

Last Update Submitted That Met QC Criteria

February 19, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 79/25.07.2024

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Demographical values could be shared. The questionaries answers are personal so only scale results may be shown.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Placenta Accreta Spectrum

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe